PCT/CA04/14[illegible] 29 SEPTEMBER 2004 (29.09.0

PA 1222135

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

September 10, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: ***60/494,549***
FILING DATE: ***August 13, 2003***

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

M. SIAS
Certifying Officer

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(b)(2).

INVENTOR(s)/APPLICANT(s)

Given Name (first and middle [if any])	Family Name or Surname	Residence (CITY AND EITHER STATE OR FOREIGN COUNTRY)
REDMOND	Mark J.	Edmonton, Alberta, CANADA
SHAW	Diana F.	Edmonton, Alberta, CANADA

☐ Additional inventors are being named on the ___ separately numbered sheets attached hereto.

TITLE OF THE INVENTION (280 characters max)

DIAGNOSTIC COMPOSITION FOR DIABETES TYPE 2 AND IMPAIRED GLUCOSE TOLERANCE, AND METHODS OF USE

CORRESPONDENCE ADDRESS

☒ Customer Number: **6449**

☐ Firm or Individual Name	Rothwell, Figg, Ernst & Manbeck, P.C.				
Address	1425 K Street, N.W.				
Address	Suite 800				
City	Washington	State	D.C.	ZIP	20005
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031

ENCLOSED APPLICATION PARTS *(check all that apply)*

☒ Specification *Number of Pages* [34]
☒ Drawing(s) *Number of Sheets* [3]
☒ Application Data Sheet. See 37 CFR 1.76
☐ CD(s), Number _____
☐ Other *(specify)* _____

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT *(check one)*

☐ Applicant claims small entity status. See 37 CFR 1.27
☐ A check or money order is enclosed to cover the filing fee
☒ The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 02-2135
☐ Payment by credit card. Form PTO-2038 is attached.

Filing Fee Amount: $160.00

Th invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.
☐ Yes, the name of the U.S. Government agency and the Government contract number are: _____

Respectfully submitted,

SIGNATURE _____ Date 13 AUGUST 2003

TYPED or PRINTED NAME JEFFREY L. IHNEN
TELEPHONE : 202-783-6040

REGISTRATION NO. 28,957
Docket Number: 2315-123

USE ONLY FOR FILING PROVISIONAL APPLICATION FOR PATENT

DIAGNOSTIC COMPOSITION FOR DIABETES TYPE 2 AND IMPAIRED GLUCOSE TOLERANCE, AND METHODS OF USE

FIELD OF THE INVENTION

The present invention relates generally to products for use in the detection of metabolic disease. In particular, the invention relates to a dry, baked test meal useful in the screening and early diagnosis of impaired glucose tolerance and type 2 diabetes.

BACKGROUND OF THE INVENTION

Disorders of carbohydrate metabolism traditionally include diabetes and impaired glucose tolerance. Diabetes is a well-recognized cause of significant morbidity and mortality. With the World Health Organization ("WHO") estimating 300 million diabetics globally by 2025, non-insulin dependent, type 2, diabetes ("type 2 diabetes") is a major public health concern. Type 2 diabetes is the most common diagnosis of patients entering dialysis programs in the United States, a major cause of vision loss and a major contributing factor in cardiac, peripheral, and cerebral vascular diseases.

The Da Qing IGT and Diabetes Study and Bayer AG STOP-NIDDM study have the objectives of determining the effects of diet, exercise and drug interventions in preventing type 2 diabetes in people with impaired glucose tolerance ("IGT"). Results to date suggest that early diagnosis and treatment of impaired glucose tolerance and type 2 diabetes to reduce hyperglycemia may reduce complications and delay the onset of type 2 diabetes.

A patient with impaired glucose tolerance displays an abnormal glucose tolerance in which the blood glucose levels are not high enough to be associated with the specific complications of diabetes. Impaired glucose tolerance is a major risk factor in the development of type 2 diabetes, peripheral vascular disease and cardiovascular disease. However, despite these facts, widespread screening for impaired glucose tolerance and asymptomatic type 2 diabetes has not been routinely conducted.

The fasting plasma glucose ("FPG") and the random plasma glucose ("RPG") tests are the most commonly utilized screening test methods for diabetes. The method for FPG requires an overnight fast, after which a blood sample is taken and blood glucose level determined. The RPG test comprises a blood glucose test regardless of the time since the last ingestion of food. The use of fasting or random glucose alone is considered to lack adequate specificity and sensitivity (Modan et al. (1994) *Diabetes Care* 17:436-439). Further, these tests cannot detect impaired glucose tolerance. However, since these are the most rapid, simple and cost effective tests, the fasting glucose and random glucose screens are the current methods of choice and recommended by the American Diabetic Association.

The accepted method of diagnosing diabetes, impaired glucose tolerance, type 2 diabetes, and hyperinsulinemia is to administer a 75-gram oral glucose tolerance test ("OGTT"). The main reason for the use of this test is that a postprandial blood glucose value is needed to make an accurate diagnosis. Glucose is used because it is easy to standardize the amount administered, it is easily stored, and its absorption is not influenced by other food factors such as protein or fat, cooking, and processing. However, the OGTT has drawbacks and is not commonly utilized as a clinical test. Thus, diabetes, impaired glucose tolerance, and hyperinsulinemia are not generally diagnosed early.

One of the drawbacks of the OGTT is the difficulty conducting the test, which requires at least an 8-hour fast and a timed blood sample 120 minutes after consuming 75 grams of liquid glucose. In addition, glucose is generally unpalatable and 75 grams is a large dose that may lead to nausea and other gastrointestinal side-effects. Moreover, the results of the OGT test are highly variable often leading to false positives and false negatives. Because of this variability, it is difficult to interpret the results of an OGTT.

Blood glucose can be tested either using venous whole blood or capillary whole blood samples, though the diagnostic levels will vary depending from where the blood is drawn. Blood glucose levels are significantly higher in capillary blood samples than they are in venous blood samples (Kuwa et al., *Clin Chim Acta* (2001) May 307 (1-2):187-92). The diagnosis of diabetes

is established if fasting venous plasma glucose is at least 160 mg/dL (7.8 mmol/L) or plasma glucose is at least 200 mg/dL (11.1 mmol/L).

Near-normal glycemic control can prevent diabetic complications. However, early interest in mass screening for diabetes to facilitate early diagnosis and prevent debilitating or fatal complications was tempered by the undesirable economic, social, physical, and psychological consequences of diagnosing diabetes. The current absence of a successfully implemented diabetes mass screening program is the result of the lack of resolution of these concerns (Harris et al. (1994) *Diabetes Care.* 17:440-445; Knowler (1994) *Diabetes Care* 17:445-450).

Current interest in diabetes screening programs have fostered studies on, for example, random capillary blood glucose measurements (Engelgau et al. (1995) *Diabetes Care* 18:463-466) and questionnaires to evaluate the prevalence of diabetes risk factors and thereby prospectively identify subjects at increased risk for undiagnosed diabetes (Herman et al. (1995) *Diabetes Care* 18:382-387). These tests have proven to be variable, empirical, and qualitative. Selecting those subjects from the general population who present risk factors merely identifies candidates for more precise and quantitative tests.

Accordingly, there is a need in the art for a more sensitive, more accurate, more acceptable, and standardized method for screening and/or diagnosis of diabetes and impaired glucose tolerance as well as a tool to assist in the management of disorders of carbohydrate metabolism.

Wolever et al. (*Diabetes Care* (1998) 21 336-340) and WO 97/02050 (Palmason and Wolever) describe the use of a solid oral diagnostic test meal for determining the postprandial concentration of a blood constituent in a vertebrate. The test meal bar disclosed in Wolever et al. comprises 41 g of starch, and 3.8 g. of total dietary fibre, while that disclosed in WO 97/02050 comprises 41-55 percent by weight of starch, and about 1.4 percent by weight of oat β-glucan. Both of these products have a high soluble fibre content.

It has been reported that the postprandial blood glucose response in subjects with normal or abnormal carbohydrate metabolism can be blunted by consumption of a high-carbohydrate, high-fibre bar (McIvor et al. (1985) *Diabetes Care* 8:274-278). In further contrast, soluble dietary fibre has been reported to impair glucose absorption (see Wursch and Pi-Sunyer Diabetes Care: 20:1774-1780; Jenkins et al. European Journal of Clinical Nutrition 56 (7): 622-628 (2002)).

Certain forms of soluble dietary fibre significantly decrease post-prandial hyperglycaemia, by inhibiting glucose uptake from the small intestine into the blood, and may improve control of blood-glucose concentration by diabetics (Jenkins et al. *Lancet* 1976 Jul 24 2(7978):172-4). The diagnostic test meal of the present invention has a low soluble fibre content, containing less than 0.2 percent by weight.

The present invention also differs significantly from diabetic meals currently on the market which contain high fibre to improve control of blood glucose concentrations, such as the "CardioBar" (Abbott Laboratories). Other products contain mixed carbohydrate sources that release glucose over time, such as the "NiteBite" (ICN Pharmaceuticals, Inc.).

The product described in U.S. Patent No. 5,545,414 was developed by Abbott Laboratories and was trademarked as the "*CardioBar*", now marketed as the "*GlucernaBar*" as a snack for diabetics. The referenced patent describes a nutritional product developed specifically to lower cholesterol. The activity of the CardioBar product is attributable to dietary fibre, in this case guar gum, which affects cholesterol uptake in the gut. The preferred mode is to incorporate about 20 percent guar gum by weight into an unbaked food bar. The guar gum present in the CardioBar may impair glucose absorption from the small intestine into the blood, and result in readings of blood glucose concentrations that do not accurately reflect the degree to which cellular uptake of glucose is controlled. These readings can therefore result in diabetic patients being misdiagnosed as normal.

For the CardioBar, the preferred source of carbohydrate is high fructose corn syrup at approximately 24 percent by weight. In 1997, the FDA allowed health claims for the lowering of

cholesterol by the inclusion of oats in a low fat diet. The CardioBar requirement of encapsulated dietary fibre (20 percent guar gum) is stated, as is the specification of low oil content.

The CardioBar human trials focused on the measurement of serum cholesterol, LDL, and HDL cholesterol. The method stated an overnight fasting and method of blood sampling, and methods for measuring serum cholesterol, LDL, and HDL concentrations. The patent utilized methods developed by Haber et al. for the measurement of satiety, plasma glucose, and serum insulin. Results relating to plasma glucose and serum insulin are not presented and indeed have not been published. The experimental results indicated that the guar gum present in the CardioBar had no effect on appetite or food intake.

U.S. Patent No. 4,496,606 by Michnowski describes a dietetic snack bar for use by Type 2 diabetics in the regulation of glucose uptake for the control of impaired glucose tolerance and reduction of insulin requirement. The patent specifically cites the requirement of 8-12 percent guar gum, 27 percent corn syrup (glucose and fructose), and 6 percent simple sugar (selected from dextrose, fructose, glucose, and galactose). The product is designed specifically to pose a barrier through which nutrients must cross before being absorbed. When combined with a high simple carbohydrate (31 percent) a steady state blood carbohydrate level is obtained which is readily controlled by a diabetic; however, there may be a concern over administering such a product to a diabetic at risk of diabetic shock. The function of the invention described in U.S. Patent No. 4,496,606 by Michnowski, is supported by U.S. Patent No. 5,545,414, and that states that U.S. Patent No. 4,496,606 uses the consumption of guar gum to improve glucose tolerance and reduce insulin requirements (by virtue of the fact that glucose absorption through the small intestine into the blood is reduced).

Such a formulation is not applicable to a diagnostic product that requires the digestive function of the diabetic to breakdown starch into glucose, which is then absorbed in real-time for an accurate measurement of glycemic response.

U.S. Patent No. 5,612,074 by Leach describes a nutrient fortified, non-cooked, food bar consisting of 38 percent dietary fibres and approximately 30 percent honey or syrup (fructose,

glucose). No measurement of glycemic response is included or considered. There may be a concern over administering such a product to a diabetic at risk of diabetic shock.

U.S. Patent No. 5,360,614 by Fox et al. describes the preparation of a composition for the slow release of carbohydrates by applying a coating of stearic acid, ethyl cellulose, or hydrogenated tallow. The result is the slow release of carbohydrate, peaking after 5 hours of digestion, which may be useful in sustained release.

U.S. Patent No. 6,248,375 by Gilles et al. describes solid matrix nutritionals designed for patients with diabetes. These nutritionals contain a source of fibre, and a combination of fructose with at least one nonabsorbent carbohydrate. The two component carbohydrate system is designed to blunt the postprandial glycemic response, and may be in the form of a bar.

It is an object of the present invention to overcome drawbacks of the prior art. The above object is met by a combination of the features of the main claims. The sub claims disclose further advantageous embodiments of the invention.

SUMMARY OF THE INVENTION

The present invention relates generally to products for use in the detection of metabolic disease. In particular, the invention relates to a dry baked test meal useful in the screening and early diagnosis of impaired glucose tolerance and type 2 diabetes.

In one aspect, the present invention provides an oral diagnostic test meal comprising a polysaccharide (complex carbohydrate) that provides a quantity of available carbohydrate effective to increase blood glucose levels in a vertebrate subject, wherein the diagnostic test meal comprises less than 0.2 percent by weight soluble fibre.

In another aspect, the present invention provides a method of diagnosing a disorder of carbohydrate metabolism in a vertebrate subject comprising:

(a) orally administering to the subject a diagnostic test meal comprising a polysaccharide that provides a quantity of available carbohydrate effective to increase blood glucose levels in a vertebrate subject, wherein the diagnostic test meal comprises less than 0.2 percent by weight fibre;

(b) assaying postprandial glucose concentration in a biological sample taken from the subject, and

(c) comparing the postprandial glucose concentration in the biological sample with a reference glucose concentration.

In an example of the above-defined method, the biological sample is blood.

The present invention also relates to the method described above, wherein the disorder of carbohydrate metabolism is selected from the group consisting of diabetes mellitus, impaired glucose tolerance, insulin resistance, non-insulin dependent diabetes, maturity onset diabetes,

gestational diabetes and hyperinsulinemia.

In a further aspect, the present invention provides a method of determining a postprandial glucose concentration in a biological sample from a vertebrate subject comprising:

(a) orally administering to the subject a diagnostic test meal comprising a polysaccharide that provides a quantity of available carbohydrate effective to increase blood glucose levels in a vertebrate subject, wherein the diagnostic test meal comprises less than 0.2 percent by weight fibre, and

(b) assaying postprandial glucose concentration in a biological sample taken from the subject.

In an even further aspect, the present invention provides a method of determining a postprandial insulin response in a vertebrate subject comprising:

(a) orally administering to the subject a diagnostic test meal comprising a polysaccharide that provides a quantity of available carbohydrate effective to increase blood glucose levels in a vertebrate subject, wherein the diagnostic test meal comprises less than 0.2 percent by weight fibre, and

(b) assaying postprandial insulin concentration in a biological sample taken from the subject.

In another aspect, the present invention provides a method of diabetes self-diagnosis and self-monitoring in a vertebrate subject, comprising:

(a) orally administering to the subject a diagnostic test meal comprising a polysaccharide that provides a quantity of available carbohydrate effective to increase blood glucose levels in a vertebrate subject, wherein the diagnostic test meal comprises less than 0.2 percent by weight fibre, and

(b) assaying postprandial glucose concentration in a biological sample taken from the subject.

In a further aspect, the present invention provides a method of managing the dosage of a drug that decreases postprandial blood glucose concentration in a vertebrate subject, comprising:

(a) orally administering to the subject a diagnostic test meal comprising a polysaccharide that provides a quantity of available carbohydrate effective to increase blood glucose levels in a vertebrate subject, wherein the diagnostic test meal comprises less than 0.2 percent by weight fibre, and

(b) assaying postprandial glucose concentration in a biological sample taken from the subject, and

(c) repeating steps (a) to (b) after administration of the drug.

In particular, the present invention relates to a method for the *in-vivo* diagnosis of a metabolic disorder, for example, diabetes and the pre-cursor of diabetes, impaired glucose tolerance, which comprises orally administering a calibrated amount of starch in a composition, allowing digestion to take place for between 30 to 60 minutes, and obtaining a blood sample for glucose estimation and analysis.

In another aspect, the present invention further provides a kit for diagnosing disorders of carbohydrate metabolism in a vertebrate subject, comprising an oral diagnostic test meal comprising a polysaccharide that provides a quantity of available carbohydrate effective to increase blood glucose levels in a vertebrate subject, wherein the diagnostic test meal comprises less than 0.2 percent by weight fibre.

In a further aspect, the present invention further provides a kit for determining postprandial glucose concentration in a biological sample from a vertebrate subject, comprising an oral diagnostic test meal comprising a polysaccharide that provides a quantity of available

carbohydrate effective to increase blood glucose levels in a vertebrate subject, wherein the diagnostic test meal comprises less than 0.2 percent by weight fibre.

In an even further aspect, the present invention provides a kit for determining a postprandial insulin response in a vertebrate subject, comprising an oral diagnostic test meal comprising a polysaccharide that provides a quantity of available carbohydrate effective to increase blood glucose levels in a vertebrate subject, wherein the diagnostic test meal comprises less than 0.2 percent by weight fibre.

In another aspect, the present invention provides a kit for diabetes self-diagnosis and self-monitoring in a vertebrate subject, comprising an oral diagnostic test meal comprising a polysaccharide that provides a quantity of available carbohydrate effective to increase blood glucose levels in a vertebrate subject, wherein the diagnostic test meal comprises less than 0.2 percent by weight fibre.

In a further aspect, the present invention provides a kit for managing the dosage of a drug that decreases postprandial glucose concentration in a vertebrate subject, comprising an oral diagnostic test meal comprising a polysaccharide that provides a quantity of available carbohydrate effective to increase blood glucose levels in a vertebrate subject, wherein the diagnostic test meal comprises less than 0.2 percent by weight fibre.

In one example, the above-defined diagnostic test meal comprises:

(a) about 35 to about 55 percent by weight polysaccharide;

(b) about 10 to about 35 percent by weight mono- and disaccharides;

(c) about 10 to about 25 percent by weight dietary fat, and

(d) about 5 to about 8 percent by weight dietary protein.

The ratio of (a) to (b) in the just defined diagnostic test meal may be from about 1.5:1 to about 2.5:1, from about 1.8:1 to about 2.5:1, or from about 1.8:1 to about 2.0:1.

In an example of the above-defined diagnostic test meal, the polysaccharide is derived from a cereal grain selected from the group consisting of barley, oat, wheat, rye, corn, maize, sorghum and millet.

In another example, the above-defined diagnostic test meal further comprises one or both of a source of insoluble dietary fibre, and a source of flavoring.

In another example, the diagnostic test meal is provided in the form of a bar or biscuit.

In a further example, the polysaccharide of the diagnostic test meal described above may be derived from whole oat flour, defatted oat flour, or both.

In another example, the monosaccharide of the above-defined diagnostic test meal may be fructose, glucose, glycerin, or a mixture of glucose and fructose.

In a further example, the disaccharide of the above-described diagnostic test meal is sucrose.

The dietary fat of the diagnostic test meal described above may comprise from about 10 percent to about 30 percent saturated fat, and from about 25 percent to about 75 percent monounsaturated fat.

Diagnostic use of the test meal composition disclosed in WO 97/02050, or any other composition containing a significant amount of soluble fibre, can produce a viscous bolus within the small intestine of a patient, which contains glucose derived from digestion of the test meal composition. Due to the viscosity of the bolus, the amount and rate of glucose absorption into the blood of the patient is reduced. Diagnostic use of these compositions may, therefore, result in a measured value of glycemic response in the patient, which does not accurately reflect the degree to which the cellular uptake of glucose is being successfully regulated. For example, measurement of the glycemic response in a diabetic following administration of a composition comprising a significant amount of a soluble fibre, may provide a blood glucose concentration

that is typical of a normal person. The use of these compositions in a diagnostic method can, therefore, lead to misdiagnosis of a diabetic subject or a subject having impaired glucose tolerance as being normal.

The test meal composition of the present invention comprises less than 20 percent of the total amount of soluble fibre contained in the diagnostic test meal disclosed in WO 97/02050. During the process of digestion of the composition of the present invention, the relatively lower amount of soluble fibre present in the composition will not significantly change the viscosity of fluid within the digestive tract, and will not, therefore, significantly affect the amount and rate of glucose absorption through the wall of the small intestine. As a result, the composition of the present invention can be used to determine a glycemic response of a patient, which accurately reflects the degree to which the cellular uptake of glucose is being successfully regulated.

The present invention has a shelf life of approximately two years, is consistent in ingredients and can be reproducibly manufactured. Furthermore, standard chemical and laboratory methods can be used in analyzing the constituents of the diagnostic test meal of the present invention for the purposes of quality assurance and quality control. Quality assurance and quality control testing of the diagnostic test meal of Wolever et al. (*Diabetes Care* (1998) 21 336-340), however, is dependent on *in-vivo* glycemic indexing.

As the test meal composition of the present invention comprises a complex carbohydrate, which is gradually digested into glucose, the risk of diabetic shock associated with its consumption is low. The selected source of starch is of such purity that a calibration in terms of glucose equivalents is possible.

This summary does not necessarily describe all necessary features of the invention but that the invention may also reside in a sub-combination of the described features.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other features of the invention will become more apparent from the following description in which reference is made to the appended drawings wherein:

Figure 1 illustrates the glycemic response to the diagnostic test of the present invention for a normal, and an IGT patient. The points represent five or four separate tests conducted on the normal or IGT patient, respectively.

Figure 2 illustrates the screening results of nine impaired glucose tolerance (IGT) patients determined using both the fasting plasma glucose test and the diagnostic test meal of the present invention.

Figure 3 illustrates the screening results of nine diagnosed diabetic patients using both the fasting plasma glucose (FPG) test and the diagnostic test meal of the present invention. Each patient was tested four times using the FPG test and the diagnostic test meal of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates generally to products for use in the detection of metabolic disease. In particular, the invention relates to a dry baked test meal useful in the screening and early diagnosis of impaired glucose tolerance and type 2 diabetes.

Central to the present invention is the discovery that the novel dry screening and/or diagnostic test meal disclosed herein produces a more precise assessment of an individuals' health with respect to diabetes or impaired glucose tolerance.

Accordingly, the present invention provides an oral diagnostic test meal for use in the screening and early diagnosis and management of diabetes.

The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, medicine, nutritional analysis, and food formulation, within the skill of the art. Such techniques are explained fully in the literature. *See*, e.g., Bergmeyer et al., eds. *Methods of Enzymatic Analysis*, Academic Press (New York), U.S. Dept. HEW (1982) *Lipid and Lipoprotein Analysis: Manual of Laboratory Operations, Lipid Research Clinics Program*, (Washington, DC), AOAC (1980) *Official Methods of Analysis* (Washington, DC), National Diabetes Group (1979) Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance, *Diabetes* 28:1039-1057, Furia (1972 and 1980) *Handbook of Food Additives*, 2d ed., Volumes I and II, CRC Press Inc. (West Palm Beach, FL), and Committee on Specifications, Committee on Food Protection, National Research Council (1980) *Food Chemicals Codex*, 3d ed., National Academy of Sciences (Washington, DC).

All publications, patents, and patent applications cited herein, whether *supra* or *infra*, are hereby incorporated by reference in their entirety.

As used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural references unless the content clearly dictates otherwise. Thus, the term "a blood glucose measurement" can include more than one such measurement.

In describing the present invention, the following terms will now be employed, and are intended to be defined as indicated below. Although reference is made to blood as a biological sample in the following definitions, the term is intended to encompass other biological samples as well.

By "dry form" is meant a product which has been baked to a dry form and has a moisture content of <5 percent.

By "glycemic response" is meant the amount of glucose produced in the blood following ingestion of a food, test meal, or the like taken at a specific postprandial time point, for example, 30, 60, 90, and/or 120 minutes. A subject's glycemic response may be expressed as a percentage of the response to a control standard, for example, a 75-gram glucose-containing beverage, eg., Glucodex® (Rougier, Inc., Camble, Quebec). Minimally the glycemic index is taken 120 minutes postprandial, most typically 180 minutes.

The "glycemic index" may be used as a basis for dietary carbohydrate exchange and as a reference for assessing the glucose response to a particular food. (*See*, Jenkins et al. (1981) *Am. J. Clin. Nutr.* 34:362-366, and Jenkins et al. (1983) *Diabetologia* 24:257-264). The glycemic index may be determined as described in Wolever et al. (1985) *Diabetes Care* 8:418-428, Wolever et al. (1991) *Am. J. Clin. Nutr.* 54:846-854, and Wolever et al. (1994) *Am. J. Clin. Nutr.* 59:1265-1269.

By "available carbohydrate" is meant the amount of total carbohydrate ingested which can be digested and absorbed. Total carbohydrate is calculated by difference, i.e., total carbohydrate ("TC") is calculated using the equation $TC = S - M - A - F - P$, where S is the weight of the food sample, M is the moisture content, A is the ash content, F is the fat content, and P is the protein content. The methods for measuring moisture, ash, fat, and protein are

described in, e.g., *AOAC Official Methods of Analysis* (1980) Washington, DC, Association of Official Analytical Chemists. Available carbohydrate is the difference between total carbohydrate and dietary fibre in a food sample. Dietary fibre can be measured, e.g., according to the method of Prosky et al. (1988) *J. Assoc. Off. Anal. Chem.* 71:1017.

By "management of disorders of carbohydrate metabolism" it is intended that the test may be used to establish and manage drug dosage.

By "medically controlled" is meant that a diagnostic test meal contains a source of carbohydrate that provides a standardized and calibrated amount of available carbohydrate which, when administered to a subject, yields a glycemic response in that subject. The present test does not require periodical recalibration as it delivers a standardized quantity of carbohydrate in each test meal.

A "reference concentration" of glucose in a biological specimen is that concentration that has been reported as normal for a non-obese, non-diabetic, healthy subject. The reference concentration may be in reference to fasting glucose or in reference to postprandial glucose concentration. Such reference concentrations are described in, for example, National Diabetes Group (1979) *Diabetes* 28:1039-1057, and WHO Expert Committee (1980) *Diabetes Mellitus*, Geneva, World Health Organization (Tech. Rep. Ser. No. 646). In addition, a reference concentration may be an intra-subject reference, i.e., a concentration of glucose or insulin in a biological sample previously obtained from the subject being retested.

By "vertebrate subject" is meant any member of the subphylum chordate, including, without limitation, mammals such as cattle, sheep, pigs, goats, and man; domestic animals such as dogs and cats; and birds, including domestic, wild and game birds such as cocks and hens including chickens, turkeys, and other gallinaceous birds. The term does not denote a particular age. Thus, both adult and newborn animals are intended to be covered.

The terms "self-diagnosis", "self-teaching", and "self-monitoring" are meant to encompass the use of the diagnostic test meal in a non-clinic setting. Thus, for example, self-

diagnosis is intended to encompass not only the use of the diagnostic test meal by a human subject on himself or herself for the diagnosis of a disorder of carbohydrate metabolism, but also the use of the diagnostic test meal by a party for the diagnosis of a disorder of carbohydrate metabolism in another vertebrate subject.

A "biological sample" may be derived from a variety of sources, e.g., human or other mammalian biological fluids or tissues, including blood (serum or plasma), urine, cerebrospinal fluid, lymph fluid, and the like.

The terms "blood glucose" is intended to mean glucose, measured in whole blood, serum, or plasma taken from a vein or a capillary bed. Typical sources of capillary blood include finger, heel, or earlobe-pricks. One of ordinary skill in the art will recognize that the blood glucose level will vary slightly depending on the source.

The glucose levels in a biological sample may be measured by any method known in the art. In this regard, glucose levels may be measured using the hexokinase method (Bergmeyer et al. (1974) in Bergmeyer et al., eds. *Methods of Enzymatic Analysis*, Academic Press (New York)). Briefly, this assay entails simultaneously incubating the biological sample with the enzyme hexokinase, which catalyzes the transfer of the γ-phosphate group from adenosine triphosphate ("ATP") to glucose to form glucose-6-phosphate and glucose-6-phosphate dehydrogenase, which, in the presence of nicotinamide-adenine dinucleotide phosphate ("NADP"), catalyzes the conversion glucose-6-phosphate to 6-phosphogluconate and reduced NADP ("NADPH"). The resultant NADPH is coupled to the reduction of iodonitrotetrazolium ("INT"), or other reagent which when chemically reduced forms a colorimetrically detectable species, to form INT-formazan.

Optionally, glucose may be measured, e.g., using glucose oxidase-catalyzed conversion of glucose to gluconic acid, thereby producing hydrogen peroxide, which may be detected colorimetrically by, for example, incubation with 4-aminoantipyrine and *p*-hydroxybenzene sulfonate or *o*-dianisidine in the presence of peroxidase to produce the colorimetrically detectable species quinoneimine dye or oxidized *o*-dianisidine, respectively. By comparison with

a standard curve generated using known quantities of glucose, the amount of glucose in the sample can be determined.

The individual components required for the above-described glucose assays, as well as kits therefore, may be obtained from any commercial source, e.g., Sigma Chemical Co. (St. Louis, MO).

The dry carbohydrate diagnostic test meal disclosed and claimed herein contains a carbohydrate source providing an amount of a polysaccharide (complex carbohydrate), such as starch, which has been calibrated and standardized to provide a selected quantity of available carbohydrate upon ingestion of the test meal by a vertebrate subject. A particular example of a polysaccharide is oat starch formulated with a minimum quantity of β–glucan from oat grain, or another cereal grain including, without limitation, any of the various cultivars of e.g., barley, oat, wheat, rye, corn, maize, sorghum, and millet, or another source, such as potato, sweet potato, canna, arrowroot, tapioca (cassava) sago, arum, triticale, rice, beans, peas, lentils, chestnuts, peanuts, inulin, lichen, or the like. Alternatively, any synthetic starch well known in the art can be included as a carbohydrate source. Other ingredients may also be included such as protein, fat, texture, and palatability enhancers and the like.

The present invention contains a physiologically balanced carbohydrate source, but need not contain the recommended dietary requirements for carbohydrate, fat and protein. The recommended daily requirements for diabetics is the same as those for normal people, with 30 percent of the daily energy requirements from fats, 10-20 percent from proteins and 40-50 percent from carbohydrates (American Diabetes Association).

In particular, the composition of the present invention has a soluble fibre content of less than 0.2 percent by weight. As a result, administration of the composition of the present invention to a subject will not significantly increase the viscosity of fluid within the small intestine, and, therefore, not result in a significant reduction in glucose absorption through the small intestine and into the blood of the subject.

The diagnostic test meal of the present invention may contain from about 35 to about 65 percent by weight, from about 35 to about 55 percent by weight, from about 45 to about 55 percent by weight, or from about 45 to about 50 percent by weight of a polysaccharide (complex carbohydrate). In addition, the test meal may contain from about 5 to about 30 percent by weight, from about 10 to about 25 percent by weight, from about 15 to about 25 percent by weight, or from about 15 to about 20 percent by weight fat, of which from about 10 percent to about 30 percent is saturated fat, from about 25 percent to about 75 percent, or from about 45 percent to about 55 percent, is monounsaturated fat, and the remainder is polyunsaturated fat. The test meal of the present application may also contain from about 2 to about 15 percent by weight, from about 5 to about 10 percent by weight, or from about 5 to about 8 percent by weight protein, and optionally about 3 to 5 grams total dietary fibre.

The ratio of the amount of the polysaccharide to the sum of the amounts of the monosaccharide and the disaccharide may be from about 1.5:1 to about 2.5:1, from about 1.7:1 to about 2.5:1, from about 1.8:1 to about 2.5:1, from about 1.8:1 to about 2.3:1, or from about 1.8:1 to about 2.0:1. In other examples, the ratio of the amount of polysaccharide to the sum of the amounts of monosaccharide and disaccharide is from about 1.5:1 to about 2.0:1, or from about 1.5:1 to about 1.8:1.

Examples of fat used in the test meal compositions of the present invention is fat obtained from vegetable oils, such as canola oil, rapeseed oil, flax oil, borage oil, safflower oil, soybean oil, coconut oil, evening-primrose oil, castor oil, olive oil, almond oil, peanut oil, linseed oil, corn oil, and maize oil, fish oils such as cod liver oil or halibut oil, extracted oat fat or the like, protein obtained from soy flour, egg albumin, ovoglobulin, wheat gluten, whey, lactoglobulin, lactalbumin, meat and blood isolates, serum albumin, fish protein isolates, legume isolates, soy protein, quinoa protein, or the like.

In order to increase the palatability of the test meal, flavoring such as apple juice, cinnamon, vanilla, lemon, or orange extracts, almond flavor, or the like may be added to the test meal. Other standard food additives may be incorporated into the test meal, for example, acidulants, anticaking agents, baking aids, bleaching agents, buffering agents, colorants, color

fixatives, cooking media, dough conditioners, emulsifiers, enzymes, firming agents, flavor enhancers, flavors, humectants, leavening agents, masticatory substances, maturing agents, neutralizers, nonnutritive sweeteners, nutrients and dietary supplements, preservatives, protein sources, salt substitutes, sequestrants, stabilizers, sweeteners, texturizers, thickeners, vitamins, and the like. *See*, e.g., Furia (1972 and 1980) *Handbook of Food Additives*, 2d ed., Volumes I and II, CRC Press Inc. (West Palm Beach, FL).

An example of a test meal, which provides 406.5 kcal of energy, comprises 50.0 grams of carbohydrate (49 percent of the meal energy) comprising starch extracted from oat groats, 19.9 grams of fat (44 percent of the meal energy) comprising vegetable and oat fat, 6.69 grams of protein (7 percent of the meal energy) comprising protein derived from oat flour and egg albumin, 4.30 grams of total dietary fibre comprising β-glucan derived from whole oat flour, and vanilla and butter flavors for flavoring.

The amount of available carbohydrate in the test meal may be calibrated to achieve a selected glycemic response or a selected glycemic index, determined as described above. A reference glycemic response may be obtained using, for example, an oral liquid glucose standard containing a quantity of glucose, for example 50 grams, 75 grams, or 100 grams of glucose. The amount of available carbohydrate in a test meal may be standardized to achieve a selected 30-minute, 45-minute, 60-minute, 90-minute, 120-minute, or the like, postprandial blood glucose response. For a test meal calibrated against an oral liquid glucose reference, the reference glycemic response may be determined using a 75-gram oral liquid glucose beverage, e.g., Glucodex®. For a test meal calibrated to achieve a selected glycemic index, a reference glycemic index may be obtained using a 50-gram carbohydrate portion of white bread. Thus, for example, the glycemic response or glycemic index obtained for a subject after ingestion of the test meal may be compared to the precalibrated glycemic index or glycemic response of the test meal.

The polysaccharide may be prepared from cereal grains, such as oats, using the method disclosed in U.S. Patent No. 4,435,429, issued to Burrows et al., the disclosure of which is hereby incorporated in its entirety by reference. Briefly, the process involves separation of endospermic tissue from other tissues in grain by first soaking the grain in an aqueous medium,

pH 3-7, at 400°C to 700°C until the grain has absorbed at least its own weight of the aqueous medium and the endosperm portion of the grain has been liquified by the action of enzymes indigenous to the cell wall. The grain is then split under pressure to release virtually all the liquified endosperm. The endosperm can then be separated from the other tissues of the grain. The grain can be whole, dehulled or hulless. The aqueous medium may contain up to about 0.1 wt. percent SO_2. Using this method, low fibre, off-white flour can be produced in the wet or dry state ready for further fractionating.

Optionally, the polysaccharide is derived from cereal grains, such as oat grains, which may be prepared using the method described in U.S. Patent No. 5,169,660, issued to Collins et al., which is hereby incorporated in its entirety by reference. The method involves first steeping the cereal grain in water for a period of time sufficient to substantially completely liquify the endosperm. The steeped grain is then macerated in an aqueous ethanol solution to liberate the liquid endosperm.

Insoluble bran is then separated and recovered from the aqueous ethanol solution and the insoluble flour is separated and recovered from the bran-free aqueous ethanol solution. Recovery of the insoluble bran and flour from the aqueous ethanol solution may be effected by passing the solution over sequentially finer mesh screens. This method is particularly useful for producing relatively pure bran and flour from oat, wheat and rye grains.

The test meal may be in any solid physical form such as a bar, wafer, biscuit, cookie, or the like. In one example, the test meal is in the form of cookies, each of which can deliver 5 grams glycemic carbohydrates. The meal can be standardized for 50 grams or 75 grams glycemic carbohydrates, or administered on a per kilogram of patient's body mass.

The complex carbohydrate within the composition of the present invention must be digested before glucose is released and absorbed. Since digestion will be specific to the test subject, the release and absorption of glucose will be specific for that individual. The absorption process will also take place in the context of a normal, solid meal and the kinetics of glucose

absorption will relate to "normal" physiological events rather than a test or specially modified meal.

As a result, the blood glucose determinations with the test meal composition of the present invention will be accurate and relate to an individual's normal physiology. This allows for the rapid detection of the diabetic state, often at a time before full-blown diabetes is established, allowing for early remedial actions to be taken.

The test meal of the present invention may be made by routine methods well known to those of skill in the art. For example, the components of the test meal may be blended in predetermined proportions with a binding agent, if necessary, selected so as to preserve the component proportions of the product, e.g., whole egg powder, or wheat gluten, to form a mixture. The mixture may be molded, pressed, poured, extruded, or otherwise formed into a desired shape. The shaped product may also be baked, steamed, dried, or otherwise processed, as required, to set the shape. *See*, e.g., U.S. Patent No. 5,200,215 to Slade et al.

The test meal disclosed herein produces a more precise (CV ≈ 3 percent-5 percent) and more physiological measurement of postprandial glucose response compared to liquid glucose beverages such as Glucodex®. Furthermore, the dry test meal produces more precise responses than liquid meals such as Enrich® (Ross Laboratories, Montreal, Canada). Thus, in using the dry test meal, it is possible to predict blood glucose response with only 3 percent-5 percent error. Accordingly, the dry test meal can be used as a substitute for the liquid 75-gram liquid glucose standard for the diagnosis and/or management of diabetes and impaired glucose tolerance or for the regulation of hypoglycemia. In addition, the test meal can be used to determine postprandial glucose response.

Conventional fasting blood glucose measurements are unreliable for the assessment of disorders of carbohydrate metabolism because as many as 39 percent of the subjects in the upper range of normal fasted glucose levels show diabetic postprandial glucose responses. Thus, they can only be found with a 60-minute or greater postprandial carbohydrate challenge. Using the novel dry test meal disclosed herein, a postprandial glucose response assessment can be initiated

30-45 minutes before clinical laboratory examination, e.g., a subject ingests the test meal 30-45 minutes before blood is drawn at the clinic. In addition, the test meal can be used for self-diagnosis, self-teaching, and blood glucose self-monitoring.

In addition, the diagnostic test meal can be used in the management of disorders of carbohydrate metabolism. In particular, the test meal can be used as a standard test meal to titrate drug dosage for the treatment of these diseases in individual subjects with oral antidiabetic agents. For example, α-glucosidase inhibitors, e.g., acarbose, are a class of drugs which improve blood glucose control in diabetics (Clissold et al. (1988) Drugs 35:214-243; Chiasson et al. (1994) Ann. Int. Med. 121:928-935). Following a liquid test meal, acarbose treatment causes a decrease in the mean glucose peak determined 90 minutes postprandial in patients with NIDDM (Chiasson et al., supra). However, flatulence, abdominal distension and diarrhea are major side effects associated with α -glucosidase inhibitors. Thus, it is desirable to titrate the dose of acarbose to that dose required to suppress postprandial plasma glucose.

The diagnostic test meal disclosed herein also affords a method by which such dosing regimens can be titrated to an optimal level. In order to assess the dosage of drugs required to decrease postprandial blood glucose a predetermined amount, a solid test meal may be administered to a subject and plasma glucose levels monitored at 0 (i.e., the 10 to 16-hour fasting level) 30, 45, 60, 90 and 120 minutes. The incremental area under the glycemic response curve is calculated geometrically, ignoring the area beneath the fasting value (Wolever et al. (1991) Am. J. Clin. Nutr. 54:846-854). This procedure is repeated after administration of the antidiabetic agent to determine if the drug produces the desired diminution in glycemic response. The dose of drug administered is then adjusted upward or downward as necessary to achieve the desired effect. The process may be repeated as often as required until the desired drug response is achieved. In addition, the efficacy of the treatment may be assessed periodically and the drug dosage adjusted as necessary.

A determination of the efficacy of an antidiabetic drug, and whether adjustment of the drug dosage is required, may be made by monitoring changes in the postprandial blood glucose concentration following administration of the drug. Acceptable limits of a drug-induced change

in postprandial blood glucose concentration as indicating either acceptable efficacy or a necessity for further titration of the dosage are well known to those of skill in the art.

For example, it is generally accepted that, in a subject that has been treated with a first dose of an antidiabetic agent, a second higher or lower dose of the agent that respectively effects a decrease or increase in blood glucose of approximately 2 mmol/L is considered equally efficacious.

An additional use for the dry test meal is in the area of self-diagnosis and self-monitoring. Using currently available techniques well known to those in the art, a subject can obtain fasting and postprandial blood samples which can be analyzed for glucose levels using, for example, the Bayer Glucometer Elite Diabetes Care System (Bayer AG, Leverkusen, Germany), LifeScan SureStep Blood Glucose Monitoring System (Lifescan, Inc., Milpitas, California), and Roche Accu-Chek Instant Blood Glucose Meter (Roche Diagnostics, Basel, Switzerland).

Referring to Figure 1, there is shown the glycemic response to the test meal of the present invention for a normal, and an IGT patient. It is clear that a glycemic response can be measured within 30-45 minutes of consuming the test meal. The response varies according to the status of the patient taking the test, and is indicative of their diagnosis. The points are the average of five or four separate tests conducted on the IGT and the normal patient, respectively.

Referring to Figure 2, there is shown the results of a screening of nine impaired glucose tolerance patients using both the fasting plasma glucose (FPG) test and the test meal of the present invention. Each patient was tested four times for the FPG test and the test meal of the present invention. Since the FPG test is unable to detect impaired glucose tolerance, all of the patients would be diagnosed as normal (except E1 who was borderline and might be recommended for retesting). Use of the test meal of the present invention, however, resulted in measured values of glycemic response, which were indicative of impaired glucose tolerance.

Figure 3 shows the results of a diabetes screening of nine diagnosed diabetics using both the fasting plasma glucose test and the test meal of the present invention. From the illustrated

data it can be seen that two of the diabetic patients were missed using the FPG screen, although each was correctly detected using the test meal of the present invention. Each patient was tested four times for the FPG test and the test meal of the present invention.

It is to be understood that while the invention has been described in conjunction with the preferred specific embodiments thereof, that the description above as well as the examples, which follow are intended to illustrate and not limit the scope of the invention. Other aspects, advantages, and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the compounds of the invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in °C, and pressure is at or near atmospheric.

Materials and Methods:

Finger-prick capillary blood samples (≈ 200 µl) were collected into fluoro-oxalate tubes and stored at -20°C for a maximum of 24 hours. Whole blood glucose was measured using a model 2300 STAT glucose analyzer (Yellow Springs Instruments, Ohio). Incremental areas under the glycemic response curves ("AUC") were calculated geometrically, ignoring area beneath the fasting value (Wolever et al. (1991) *Am. J. Clin. Nutr.* 54:846-854).

The mean and standard deviation ("SD") of the results for three repeats of each test meal (unless otherwise indicated) were calculated for each subject and the coefficient of variation ("CV") was calculated by expressing the SD as a percent of the mean. Where appropriate, analysis of variance was performed with subject and test meal as the variables, and the Neuman-Kuels procedure used to adjust for multiple comparisons.

Plasma glucose was measured using the hexokinase method (Bergmeyer et al. (1974) in Bergmeyer et al., eds. *Methods of Enzymatic Analysis*, Academic Press (New York)).

All procedures involving human subjects were approved by the University of Toronto Human Subjects Review Committee, the University of Alberta Ethics Committee or other appropriate review committee.

EXAMPLE 1. Solid Oral Carbohydrate Diagnostic Test Meal

The following components were combined in the amounts indicated below in Table I to produce a wet product for use in preparing the test meal compositions of the present invention.

Table I:

Ingredient	Grams	wt. % total
Sugar-granulated	110	8.1
Fructose	135	9.94
Baking soda	6.6	0.49
Baking powder	8.8	0.65
Butter flavour	3.1	0.23
Vanilla flavour	1	0.07
Salt	1.76	0.13
Whole oat flour	441	32.47
Defatted oat flour	244	17.97
Whey powder	29.9	2.2
Shortening	129.3	9.52
Invert sugar	129.3	9.52
Soy lecithin	5.71	0.42
Liquid whole egg	56.3	4.15
Water	56.3	4.15

A typical analysis of a 100-gram solid oral diagnostic test meal of the present invention is given in Table II below.

Table II:

	Best Mode for 50 grams carbohydrate	Source
Meal Weight	100 grams	
Carbohydrate	50.0 grams (200 kcal; 49% of total energy)	oat starch, oat flour, and sugars
Fat	19.9 grams (179 kcal; 44% of total energy)	whole oat flour and shortening
Protein	6.69 grams (27 kcal; 7% of total energy)	oat flour and egg albumin
Total Dietary Fibre	4.30 grams (<0.2 grams soluble fiber, such as β-glucan)	oat flour
Flavoring		vanilla and butter flavors

Example 2. Glycemic Responses to Diabetes Screening Product

One normal (M2) and one IGT subject (M4), each in the fasted state, consumed the test meal composition of the present invention to provide a load of 50 grams of carbohydrate. Blood glucose measurements, utilizing a Bayer Glucometer and Elite test strips were performed at various time points before and after consumption of the test meal composition. The glucose measurements in mmol/L are shown in Figure 1. The measurements were taken after consuming the test meal on four different occasions following an overnight fast.

Example 3. Comparison of Reproducibility of the Glycemic Responses to Oral Glucose Tolerance Tests

Three groups of adults (≥ 18 years of age) were studied with 9 volunteers in each group: nonobese (body mass index ("BMI"), BMI <27 kg/m^2) normal subjects; subjects with impaired glucose tolerance ("IGT") within the last twelve months; and subjects with non-insulin dependent (type 2) diabetes treated by diet alone. The subjects were studied after 10-12 hour overnight fasts on two separate mornings over a two-week period.

Subjects consumed either 75 grams of glucose in 300 ml orange-flavored water (Glucodex®) or a 100-gram dry carbohydrate diagnostic test meal. The order of tests was randomized, with half the subjects consuming the oral glucose meal test first, and half the test meal first.

The glucose solution was taken with 250 ml water, and test meals were taken with 450 ml water. Test meals were consumed within 10 minutes.

Both venous and capillary blood samples were obtained at each time point. The capillary blood sample was taken from a finger prick immediately after the venous sample had been obtained by way of an intravenous cannula. Blood samples were collected prior to (t_0 = start of test meal consumption) and 30, 60, 90, and 120 minutes after starting to eat and whole blood glucose was analyzed as described above. Incremental areas under the glycemic response curves were calculated by the method described above.

The mean fasting blood glucose concentration was similar before each of the two test meals. After glucose ingestion, mean blood glucose was significantly greater than after th test meal at every time point. The incremental area under the curve after glucose (mmol•min/L) was greater than after the test meal (mmol•min/L) ($p < 0.01$).

The present invention has been described with regard to preferred embodiments. However, it will be obvious to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as described herein. In the specification the word "comprising" is used as an open-ended term, substantially equivalent to the phrase "including but not limited to", and the word "comprises" has a

corresponding meaning. Citation of references is not an admission that such references are prior art to the present invention.

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. An oral diagnostic test meal comprising a polysaccharide that provides a quantity of available carbohydrate effective to increase blood glucose levels in a vertebrate subject, wherein the diagnostic test meal comprises less than 0.2 percent by weight soluble fibre.

2. The oral diagnostic test meal according to claim 1, comprising:

(a) about 35 to about 55 percent by weight polysaccharide;

(b) about 10 to about 35 percent by weight mono- and disaccharides;

(c) about 10 to about 25 percent by weight dietary fat, and

(d) about 5 to about 8 percent by weight dietary protein.

3. The oral diagnostic test meal according to claim 2, wherein the ratio of (a) to (b) is from about 1.5:1 to about 2.5:1.

4. The diagnostic test meal of claim 2, wherein the ratio of (a) to (b) is from about 1.8:1 to about 2.5:1.

5. The diagnostic test meal of claim 2, wherein the ratio of (a) to (b) is from about 1.8:1 to about 2.0:1.

6. The diagnostic test meal of claim 2, further comprising one or both of a source of insoluble dietary fibre, and a source of flavoring.

7. The diagnostic test meal of claim 2, wherein the test meal is provided in the form of a bar or biscuit.

8. The diagnostic test meal of claim 2, wherein the polysaccharide is derived from a cereal grain selected from the group consisting of barley, oat, wheat, rye, corn, maize, sorghum and millet.

9. The diagnostic test meal of claim 2, wherein the polysaccharide is derived from whole oat flour, defatted oat flour, or both.

10. The diagnostic test meal of claim 2, wherein the monosaccharide is fructose, glucose, or a mixture of glucose and fructose.

11. The diagnostic test meal of claim 2, wherein the disaccharide is sucrose.

12. The diagnostic test meal of claim 2, wherein said dietary fat comprises from about 10 percent to about 30 percent saturated fat, and about 25 percent to about 75 percent monounsaturated fat.

13. A method of diagnosing a disorder of carbohydrate metabolism in a vertebrate subject comprising:

(a) orally administering the oral diagnostic test meal of claim 1 to the subject;

(b) assaying postprandial glucose concentration in a biological sample taken from the subject, and

(c) comparing the postprandial glucose concentration in the biological sample with a reference glucose concentration.

14. The method of claim 13, wherein the biological sample is blood.

15. The method of claim 13, wherein the disorder of carbohydrate metabolism is selected from the group consisting of diabetes mellitus, impaired glucose tolerance, insulin resistance, non-insulin dependent diabetes, maturity onset diabetes, gestational diabetes and hyperinsulinemia.

16. The method of claim 13, wherein the polysaccharide in the diagnostic test meal is derived from a cereal grain selected from the group consisting of barley, oat, wheat, rye, corn, maize,

sorghum and millet.

17. The method of claim 16, wherein the cereal grain is oat.

18. The method of claim 13, wherein the diagnostic test meal is provided in the form of a bar or biscuit.

19. A method of determining a postprandial glucose concentration in a biological sample from a vertebrate subject comprising:

(a) orally administering the oral diagnostic test meal of claim 1 to the subject, and

(b) assaying postprandial glucose concentration in a biological sample taken from the subject.

20. A method of determining a postprandial insulin response in a vertebrate subject comprising:

(a) orally administering the oral diagnostic test meal of claim 1 to the subject, and

(b) assaying postprandial insulin concentration in a biological sample taken from the subject.

21. A method of diabetes self-diagnosis and self-monitoring in a vertebrate subject, comprising:

(a) orally administering the oral diagnostic test meal of claim 1 to the subject, and

(b) assaying postprandial glucose concentration in a biological sample taken from the subject.

22. A kit for diagnosing disorders of carbohydrate metabolism in a vertebrate subject, comprising the oral diagnostic test meal of claim 1.

23. A kit for determining postprandial glucose concentration in a biological sample from a vertebrate subject comprising the oral diagnostic test meal of claim 1.

24. A kit for determining a postprandial insulin response in a vertebrate subject comprising the oral diagnostic test meal of claim 1.

25. A kit for diabetes self-diagnosis and self-monitoring in a vertebrate subject comprising the oral diagnostic test meal of claim 1.

ABSTRACT OF THE INVENTION

A solid oral diagnostic test meal is provided that contains a polysaccharide that provides a medically controlled quantity of available carbohydrate when the meal is ingested by a vertebrate subject. In addition, methods and kits are provided for using the diagnostic test meal to monitor postprandial glucose and insulin levels, to diagnose disorders of carbohydrate metabolism, to manage subjects being treated with antidiabetic agents and to self-diagnose diabetes and self-manage diet and antidiabetic drug dosage.


Plasma Glucose Concentration (mmol/L)
10
9
8
7
6
5
4
3
-60
30
90
Time (minutes) Relative to Ingestion of Test Meal
M2-1
M2-2
M2-3
M2-4
M4-1
M4-2
M4-3
M4-4
M4-5

FIGURE 1


Fasting Plasma Glucose
12
10
8
6
4
Plasma Glucose
(mmol/L)
Diabetic
Normal
C4
C6
C7
E1
E10
E7
E9
M3
T3
Test Meal
12
10
8
6
4
Norm
Impaired Glucose Tolerance
Normal
C4
C6
C7
E1
E10
E7
E9
M3
T3
Patient

FIGURE 2


Fasting Plasma Glucose
Missed DM
Diabetic
Normal
Plasma Glucose
(mmol/L)
16
14
12
10
8
6
4
C10 C11 E6 M5 M7 M8 T1 T5 V4
Test Meal
Diabetic
Impaired Glucose Tolerance
Normal
Patient

FIGURE 3